Lattice Biologics Ltd. LBLTF
OTC PK
| 06/30/2021 | 03/31/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -38.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -38.06% | |||
| Cost of Revenue | -- | 28.63% | |||
| Gross Profit | -- | -83.37% | |||
| SG&A Expenses | -92.34% | 21.64% | |||
| Depreciation & Amortization | -- | 36.98% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -96.47% | 26.21% | |||
| Operating Income | 88.65% | -440.08% | |||
| Income Before Tax | 91.93% | 54.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 91.93% | 54.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 91.93% | 54.39% | |||
| EBIT | 88.65% | -440.08% | |||
| EBITDA | 121.68% | -1,561.03% | |||
| EPS Basic | 93.75% | 67.03% | |||
| Normalized Basic EPS | 95.00% | 66.67% | |||
| EPS Diluted | 93.75% | 67.03% | |||
| Normalized Diluted EPS | 95.00% | 66.67% | |||
| Average Basic Shares Outstanding | 28.82% | 37.19% | |||
| Average Diluted Shares Outstanding | 28.82% | 37.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||